KCNJ11 and diabetes mellitus: Sulfonylureas (SU) are a class of drugs that are effective in treating diabetes patients with activating mutations in KCNJ11; furthermore, SU treatment also correlates with some improvement in neurodevelopmental outcomes16,17.